Oral hearings heard the USPTO side with MSD (Merck) over a term extension for a reissued patent, in a case set to have huge implications for pharma market exclusivity, reports Marisa Woutersen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback